Kraig Biocraft Laboratories Confirms Spider Silk Production Operations Unaffected by Southeast Asia Typhoons due to Strategic Relocations to Highland Over Last 24 Months
Globenewswire· 2025-11-03 20:05
ANN ARBOR, Mich., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced that its production operations in Vietnam remain fully secure and uninterrupted following the recent series of typhoons that have impacted parts of Southeast Asia. Kraig Labs confirmed that its spider silk production facilities and infrastructure sustained no damage or disruption, including its mulberry feedstock supplies, ...
Vertex Announces Third Quarter 2025 Financial Results and $150 Million Class A Common Stock Repurchase Program
Globenewswire· 2025-11-03 20:05
核心观点 - 公司公布2025年第三季度财务业绩,实现两位数收入增长和强劲盈利能力,并宣布首次股票回购计划 [1][2] 第三季度财务业绩 - 总收入为1.92112亿美元,同比增长12.7% [5] - 软件订阅收入为1.64824亿美元,同比增长12.7% [5] - 云收入为9200万美元,同比增长29.6% [5] - 年度经常性收入(ARR)为6.482亿美元,同比增长12.4% [5] - 运营收入为430万美元,低于去年同期的490万美元 [5] - 非GAAP运营收入为3710万美元,高于去年同期的3340万美元 [5] - 净收入为400万美元,低于去年同期的720万美元 [5] - 调整后税息折旧及摊销前利润(Adjusted EBITDA)为4349.3万美元,高于去年同期的3862.3万美元 [5] - 调整后税息折旧及摊销前利润率为22.6%,与去年同期的22.7%基本持平 [5] 关键业务指标 - 截至2025年9月30日,每位直接客户的平均年收入(AARPC)为133,484美元,高于去年同期的118,800美元 [5] - 净收入留存率(NRR)为107%,低于去年同期的111% [5] - 总收入留存率(GRR)为95%,与去年同期持平 [5] - 直接客户数量为4,856个,间接客户数量为516个,总客户数量为5,372个 [21] 管理层评论与展望 - 首席执行官David DeStefano表示,云迁移和全球税制日益复杂化将继续推动对公司解决方案的强劲需求 [2] - Christopher Young将于本月接任总裁兼首席执行官,其拥有领导大型科技公司及在微软推动人工智能发展的经验 [2] - 第四季度收入指引为1.92亿美元至1.96亿美元,调整后税息折旧及摊销前利润指引为4000万美元至4200万美元 [6] - 全年收入指引为7.457亿美元至7.497亿美元,云收入增长指引为28%,调整后税息折旧及摊销前利润指引上调至1.591亿美元至1.611亿美元 [6][7] 资本分配与股票回购 - 董事会授权一项股票回购计划,允许公司回购最多1.5亿美元的A类普通股 [8] - 回购计划没有终止日期,可根据市场情况通过公开市场或私下协商交易等方式进行 [8][9] 非GAAP财务指标 - 非GAAP毛利率为73.9%,与去年同期的74.0%基本持平 [39] - 非GAAP净收入为2858.2万美元,非GAAP稀释每股收益为0.17美元 [39] - 自由现金流为3015.2万美元,自由现金流利润率为15.7%,高于去年同期的10.8% [39]
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
Globenewswire· 2025-11-03 20:05
LOS ALTOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Monday, November 10, 2025, at 3:30 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive webs ...
OHA Leads Private Financing Supporting FleetPride’s Merger with TruckPro
Globenewswire· 2025-11-03 20:00
New York, New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Oak Hill Advisors (“OHA”) served as Administrative Agent and Lead Left Arranger for a private unitranche financing supporting the recapitalization and merger of FleetPride, Inc. (“FleetPride”) with TruckPro, LLC (“TruckPro”), the two largest distributors of aftermarket parts for heavy-duty trucks in the United States. FleetPride is a portfolio company of American Securities. OHA is the largest holder of the newly raised debt facility, reinforcing its lo ...
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025
Globenewswire· 2025-11-03 20:00
Company to Host Conference Call at 8:30am ETREHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of the U.S. financial markets on Mo ...
Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler
Globenewswire· 2025-11-03 20:00
WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that David Amsellem, Sr. Research Analyst at Piper Sandler, will host a live fireside chat with the Company’s management team on November 6, 2025 at 12:00 p.m. ET. The discussion will focus on the Company’s product candida ...
Conavi Expands Leadership Team to Support Next Phase of U.S. Commercialization
Globenewswire· 2025-11-03 20:00
- Mark Quick Appointed Chief Financial Officer, Bringing Extensive Public Company Capital Markets Expertise -- Current CFO, Stefano Picone, will take on a Transitional Strategic Role to Support Leadership Continuity During Growth Phase -- Leadership additions follow submission of next-generation Novasight™ to the FDA for 510(k) clearance - TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Conavi Medical (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and ...
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
Globenewswire· 2025-11-03 20:00
-Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in 2025-HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today a ...
Mobix Labs and Peraso Enter Cooperative Discussions Toward a Potential Acquisition
Globenewswire· 2025-11-03 20:00
IRVINE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. (Nasdaq: MOBX), a rapidly growing fabless semiconductor and connectivity company serving the defense, aerospace, and high-reliability markets, today announced that it has entered into a mutual confidentiality agreement with Peraso, Inc. (Nasdaq: PRSO) to begin cooperative discussions toward a potential acquisition. The agreement creates a structured and collaborative framework for the confidential exchange of information as the two companies ...
Canterra Minerals Announces Commencement of Drilling on the Wilding Gold Project, Newfoundland
Globenewswire· 2025-11-03 20:00
项目启动与地质背景 - 公司在Wilding黄金项目上启动了新高品位黄金靶区的钻探工作 [1] - 新的地质认识来源于公司2025年夏季项目及相邻的Equinox Gold公司于2025年开设的Valentine矿山的公开数据 [2] - 新靶区显示出在55公里长的含金走廊带(该走廊带也赋存着Valentine矿山的矿床)内石英脉系统中存在高品位黄金的巨大潜力 [2] 钻探计划与目标详情 - 计划进行总进尺1,200米的大直径(HQ)岩心钻探,共设计15个钻孔 [6] - 钻探将测试已知剪切带沿线的堆叠伸展石英-金-电气石-黄铁矿脉组,检验以往未钻探过的几何形态 [6] - 靶区由2025年夏季野外工作和勘探结果、新重新解释的IP地球物理数据以及历史工作共同确定 [6] - 已确认赋存大部分最高品位矿化的伸展脉靶区被解释为与先前钻孔平行,代表了一种新的定向模型 [6] 具体靶区与技术方法 - Elm、Alder和Cedar靶区:历史槽探和钻探(Antler Gold, 2016–2017; Canterra, 2021)曾从剪切带赋存的矿脉中获得显著金品位,重新解释表明最高金富集出现在横切主剪切带的斜向伸展脉组中 [7] - 地球物理异常:重新处理的IP数据显示电阻率异常与已知石英脉吻合,并圈定了多个具有新脉群潜力的先前未测试靶区 [7] - 高精度测绘:对伸展脉组的详细构造测绘优化了新靶区的几何形态,以便进行最佳钻探测试 [7] - 钻探定向:钻机设置将以相对于历史钻探更浅的角度向西南方向钻进,以测试与Valentine矿山类似的堆叠高品位伸展脉 [7] - 孔内数据整合:钻后光学钻孔电视测量将验证矿脉产状,并将其纳入3D构造和矿脉模型,用于后续靶区定位 [7] 公司战略与项目定位 - 过去四年公司系统性地整合了资源并扩大了在纽芬兰中部矿区的土地位置 [4] - Wilding项目被解释为覆盖了赋存Valentine金矿矿床的构造走廊带约55公里的延伸部分 [15] - 公司的黄金项目紧邻Equinox Gold的Valentine矿山,该矿山预计将成为纽芬兰最大的金矿和加拿大顶级黄金生产商之一 [15]